| 000 | 00901 a2200253 4500 | ||
|---|---|---|---|
| 005 | 20250516100912.0 | ||
| 264 | 0 | _c20121126 | |
| 008 | 201211s 0 0 fre d | ||
| 022 | _a1769-6917 | ||
| 024 | 7 |
_a10.1684/bdc.2012.1609 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aLevêque, Dominique | |
| 245 | 0 | 0 |
_a[Anticancer agents: has the maximal tolerated price been reached?]. _h[electronic resource] |
| 260 |
_bBulletin du cancer _cSep 2012 |
||
| 300 |
_a808-10 p. _bdigital |
||
| 500 | _aPublication Type: English Abstract; Journal Article | ||
| 650 | 0 | 4 |
_aAntineoplastic Agents _xeconomics |
| 650 | 0 | 4 |
_aCost Control _xeconomics |
| 650 | 0 | 4 | _aCosts and Cost Analysis |
| 650 | 0 | 4 | _aDrug Costs |
| 650 | 0 | 4 | _aInsurance Coverage |
| 773 | 0 |
_tBulletin du cancer _gvol. 99 _gno. 9 _gp. 808-10 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1684/bdc.2012.1609 _zAvailable from publisher's website |
| 999 |
_c21903882 _d21903882 |
||